Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Hanmi Pharmaceutical Unveils FAP-Targeting Anticancer Platform to Address Tumor Microenvironment

Hanmi Pharmaceutical has unveiled a next-generation anticancer modality designed to target not only cancer cells but also the tumor microenvironment, expanding its drug discovery efforts into a new area of oncology.The Korean pharmaceutical company said on Oct. 6 that it presented preclinical resear

Hanmi Pharmaceutical has revealed a novel anticancer platform aimed at targeting both cancer cells and the tumor microenvironment, broadening its oncology research scope. On October 6, the Korean company showcased preclinical data on a small-molecule drug conjugate (SMDC) designed to tackle fibroblast activation protein (FAP) during Discovery on Target 2026 in Boston, which took place from September 28 to October 1.

The objective is to overcome certain limitations linked to antibody-drug conjugates (ADCs) by employing smaller molecules that can more readily navigate through tumors to target intratumoral sites.

Unlike ADCs, which have a molecular weight of around 150 kDa or higher, potentially impeding their ability to penetrate solid tumors, the SMDC's smaller size allows it to better penetrate the tumor tissue and the surrounding tumor microenvironment. This environment is often densely populated with cancer-associated fibroblasts (CAFs) and components of the extracellular matrix, making it difficult for drugs to reach their intended targets.

Hanmi Pharmaceutical chose FAP as the target for its new modality due to its high expression in CAFs within the tumor microenvironment, and its limited presence in most normal adult tissues. Elevated levels of FAP have also been observed across various solid tumors, including lung cancer, soft tissue sarcoma, and gastrointestinal cancers like pancreatic and colorectal cancer.

To identify the novel small molecule, Hanmi utilized its DNA-Encoded Library (DEL) screening technology. After identifying a class of molecules that selectively bind to FAP, the company developed an SMDC by coupling a cytotoxic payload to the FAP-targeting molecule. The platform incorporates a linker that remains stable in the bloodstream but becomes activated specifically in the tumor microenvironment, allowing the drug payload to act at the precise location of the tumor.

Preclinical studies showcased the SMDC's antitumor activity in mouse models implanted with FAP-expressing cells. The research also demonstrated strong inhibition of tumor growth and prolonged survival in an orthotopic pancreatic cancer mouse model. Unlike conventional ADC strategies that target specific antigens on individual cancer cells, the SMDC approach focuses on FAP expressed by CAFs, a common feature in the tumor microenvironment across multiple cancer types.

This method has the potential to extend the therapeutic approach from directly targeting cancer cells to addressing the broader tumor microenvironment that supports tumor growth.

The findings will be presented at the “Nature Conference – Next Generation Cancer Therapeutics,” held from October 6 to 8 at the MD Anderson Cancer Center in Texas. This conference highlights Hanmi Pharmaceutical's broader initiative to diversify its research portfolio beyond metabolic diseases, including obesity, into next-generation oncology modalities.

According to a Hanmi Pharmaceuticals spokesperson, "The SMDC modality differs from conventional ADCs by targeting FAP expressed in cancer-associated fibroblasts within the tumor microenvironment, as opposed to depending on the expression of a specific antigen on individual cancer cells. The findings demonstrate the potential of this approach to expand the therapeutic target from cancer cells themselves to the surrounding tumor microenvironment."

Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at koreaittimes.com →

More in Health & Medicine

More from Tuesday 6 October →